MEDCL MedinCell S.A.
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.…
Industry Peers
BiotechnologyKey Statistics
About MedinCell (EPA: MEDCL)
›
MedinCell (EPA: MEDCL) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 141 employees.
The shares were at 27.26 EUR on 19 November 2026, down 3.5% over 52 weeks. Its 52-week range is 19.69 EUR to 32.38 EUR: the price is 15.8% below the high and 38.4% above the low.
Its market capitalisation is 980.51M EUR.
MedinCell reports an operating margin of -85.4% and revenue down 44.6% year over year.
It holds more cash than debt, a net cash position of 12.91M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 9 analysts cover the stock; their mean price target of 36.18 EUR is 32.7% above the current price. The next earnings report is expected on 8 December 2026.